Anesthetic cardioprotection: The role of adenosine

Current Pharmaceutical Design

Volumn 20, Issue 36, 2014, Pages 5690-5695

  Bonney, Stephanie ^a   Hughes, Kelly ^a   Eckle, Tobias ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Adenosine; Cardioprotection; Circadian; Heart ischemia; Per2; Preconditioning; Volatile anesthetics

Indexed keywords

ADENOSINE; ANESTHETIC AGENT; INHALATION ANESTHETIC AGENT; ISOFLURANE; ADENOSINE A2B RECEPTOR;

ARTICLE; BACTERIAL CELL WALL; CIRCADIAN RHYTHM; CORONARY ARTERY OCCLUSION; HEART MUSCLE ISCHEMIA; HEART MUSCLE METABOLISM; HEART PROTECTION; HUMAN; ISCHEMIC POSTCONDITIONING; ISCHEMIC PRECONDITIONING; META ANALYSIS (TOPIC); PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; ANIMAL; DRUG EFFECTS; HEART INFARCTION PREVENTION; METABOLISM; MOUSE; MYOCARDIAL ISCHEMIA; MYOCARDIAL REPERFUSION INJURY; PATHOPHYSIOLOGY; PROCEDURES; SIGNAL TRANSDUCTION;

ADENOSINE; ANESTHETICS, INHALATION; ANIMALS; HUMANS; ISCHEMIC POSTCONDITIONING; ISCHEMIC PRECONDITIONING, MYOCARDIAL; MICE; MYOCARDIAL ISCHEMIA; MYOCARDIAL REPERFUSION INJURY; RECEPTOR, ADENOSINE A2B; SIGNAL TRANSDUCTION;

EID: 84925738555     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612820666140204102524     Document Type: Article

References (69)

1. Go AS, Mozaffarian D, Roger VL, et al. on behalf of the American Heart Association Statistics C, Stroke Statistics S. Heart Disease and Stroke Statistics-2013 Update: A Report From the American Heart Association. Circulation 2013; 127: e6-e245.
2. Mangano DT, Browner WS, Hollenberg M, London MJ, Tubau JF, Tateo IM. Association of perioperative myocardial ischemia with cardiac morbidity and mortality in men undergoing noncardiac surgery. The Study of Perioperative Ischemia Research Group. N Engl J Med 1990; 323: 1781-8.
3. De Hert SG. Cardioprotection in anesthesia. Minerva Anestesiol 2008; 74: 259-70.
4. Frank A, Bonney M, Bonney S, Weitzel L, Koeppen M, Eckle T. Myocardial Ischemia Reperfusion Injury: From Basic Science to Clinical Bedside. Semin Cardiothorac Vasc Anesth 2012.
5. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 1986; 74: 1124-36.
6. Eisen A, Fisman EZ, Rubenfire M, et al. Ischemic preconditioning: nearly two decades of research. A comprehensive review. Atherosclerosis 2004; 172: 201-10.
7. Alsaddique AA. Ischemic preconditioning: the endogenous power-a review of the literature. Angiology 2000; 51: 355-60.
8. Reimer KA, Jennings RB. Ischemic preconditioning: a brief review. Basic Res Cardiol 1996; 91: 1-4.
9. Thibault H, Piot C, Staat P, et al. Long-term benefit of postconditioning. Circulation 2008; 117: 1037-44.
10. Xue F, Yang X, Zhang B, Zhao C, Song J, Jiang T, Jiang W. Postconditioning the human heart in percutaneous coronary intervention. Clin Cardiol 2010; 33: 439-44.
11. Jin ZX, Zhou JJ, Xin M, et al. Postconditioning the human heart with adenosine in heart valve replacement surgery. Ann Thorac Surg 2007; 83: 2066-72.
12. Darling CE, Solari PB, Smith CS, Furman MI, Przyklenk K. 'Postconditioning' the human heart: multiple balloon inflations during primary angioplasty may confer cardioprotection. Basic Res Cardiol 2007; 102: 274-8.
13. Staat P, Rioufol G, Piot C, et al. Postconditioning the human heart. Circulation 2005; 112: 2143-8.
14. Zhou C, Liu Y, Yao Y, et al. Beta-blockers and volatile anesthetics may attenuate cardioprotection by remote preconditioning in adult cardiac surgery: A Meta-analysis of 15 Randomized Trials. J Cardiothorac Vasc Anesth.
15. Van Allen NR, Krafft PR, Leitzke AS, Applegate Ii RL, Tang J, Zhang JH. The role of volatile anesthetics in cardioprotection: a systematic review. Med Gas Res; 2: 22.
16. De Hert SG. Cardioprotection by volatile anesthetics: what about noncardiac surgery? J Cardiothorac Vasc Anesth; 25: 899-901.
17. Jovic M, Krivokapic B, Babic M, Nezic D, Dukanovic B, Stevanovic P. [Prospects of cardioprotection by volatile anesthetics]. Med Pregl; 63: 393-8.
18. Pagel PS. Cardioprotection by volatile anesthetics: established scientific principle or lingering clinical uncertainty? J Cardiothorac Vasc Anesth 2009; 23: 589-93.
19. Lorsomradee S, Cromheecke S, De Hert SG. Cardioprotection with volatile anesthetics in cardiac surgery. Asian Cardiovasc Thorac Ann 2008; 16: 256-64.
20. Landoni G, Fochi O, Zangrillo A. Cardioprotection by volatile anesthetics in noncardiac surgery? No, not yet at least. J Am Coll Cardiol 2008; 51: 1321; author reply 1321-2.
21. De Hert SG. Cardioprotection with volatile anesthetics: clinical relevance. Curr Opin Anaesthesiol 2004; 17: 57-62.
22. Pratt PF, Jr., Wang C, Weihrauch D, et al. Cardioprotection by volatile anesthetics: new applications for old drugs? Curr Opin Anaesthesiol 2006; 19: 397-403.
23. Kalenka A, Maurer MH, Feldmann RE, Kuschinsky W, Waschke KF. Volatile anesthetics evoke prolonged changes in the proteome of the left ventricule myocardium: defining a molecular basis of cardioprotection? Acta Anaesthesiol Scand 2006; 50: 414-27.
24. Bienengraeber MW, Weihrauch D, Kersten JR, Pagel PS, Warltier DC. Cardioprotection by volatile anesthetics. Vascul Pharmacol 2005; 42: 243-52.
25. De Hert SG, Turani F, Mathur S, Stowe DF. Cardioprotection with volatile anesthetics: mechanisms and clinical implications. Anesth Analg 2005; 100: 1584-93.
26. Tanaka K, Ludwig LM, Kersten JR, Pagel PS, Warltier DC. Mechanisms of cardioprotection by volatile anesthetics. Anesthesiology 2004; 100: 707-21.
27. Patel HH, Ludwig LM, Fryer RM, Hsu AK, Warltier DC, Gross GJ. Delta opioid agonists and volatile anesthetics facilitate cardioprotection via potentiation of K(ATP) channel opening. FASEB J 2002; 16: 1468-70.
28. Kersten JR, Orth KG, Pagel PS, Mei DA, Gross GJ, Warltier DC. Role of adenosine in isoflurane-induced cardioprotection. Anesthesiology 1997; 86: 1128-39.
29. Eckle T, Hartmann K, Bonney S, et al. Adora2b-elicited Per2 stabilization promotes a HIF-dependent metabolic switch crucial for myocardial adaptation to ischemia. Nat Med 2012; 18: 774-82.
30. Eckle T, Krahn T, Grenz A, et al. Cardioprotection by ecto-5'-nucleotidase (CD73) and A2B adenosine receptors. Circulation 2007; 115: 1581-90.
31. Kuno A, Critz SD, Cui L, et al. Protein kinase C protects preconditioned rabbit hearts by increasing sensitivity of adenosine A2b-dependent signaling during early reperfusion. J Mol Cell Cardiol 2007; 43: 262-71.
32. Philipp S, Yang XM, Cui L, Davis AM, Downey JM, Cohen MV. Postconditioning protects rabbit hearts through a protein kinase Cadenosine A2b receptor cascade. Cardiovasc Res 2006; 70: 308-14.
33. Reimer KA, Murry CE, Jennings RB. Cardiac adaptation to ischemia. Ischemic preconditioning increases myocardial tolerance to subsequent ischemic episodes. Circulation 1990; 82: 2266-8.
34. Jennings RB, Murry CE, Reimer KA. Preconditioning myocardium with ischemia. Cardiovasc Drugs Ther 1991; 5: 933-8.
35. Schober P, Oprea G, Mersmann J, Nebert A, Zacharowski K, Zacharowski PA. Lipoteichoic acid induces delayed myocardial protection in isolated rat hearts: a comparison with endotoxin. Resuscitation 2008; 79: 311-5.
36. Koch A, Boehm O, Zacharowski PA, et al. Inducible nitric oxide synthase and heme oxygenase-1 in the lung during lipopolysaccharide tolerance and cross tolerance. Crit Care Med 2007; 35: 2775-84.
37. Kanczkowski W, Morawietz H, Ziegler CG, et al. Pam3CSK4 and LTA-TLRs ligands associated with microdomains induce IL8 production in human adrenocortical cancer cells. Horm Metab Res 2007; 39: 457-60.
38. Bornstein SR, Zacharowski P, Schumann RR, et al. Impaired adrenal stress response in Toll-like receptor 2-deficient mice. Proc Natl Acad Sci USA 2004; 101: 16695-700.
39. Chatterjee PK, Zacharowski K, Cuzzocrea S, et al. Lipoteichoic acid from Staphylococcus aureus reduces renal ischemia/reperfusion injury. Kidney Int 2002; 62: 1249-63.
40. Zacharowski K, Chatterjee PK, Thiemermann C. Delayed preconditioning induced by lipoteichoic acid from B. subtilis and S. aureus is not blocked by administration of 5-hydroxydecanoate. Shock 2002; 17: 19-22.
41. Zacharowski K, Berkels R, Olbrich A, et al. The selective guanylate cyclase inhibitor ODQ reduces multiple organ injury in rodent models of Gram-positive and Gram-negative shock. Crit Care Med 2001; 29: 1599-608.
42. Zacharowski K, Olbrich A, Cuzzocrea S, Foster SJ, Thiemermann C. Membrane-permeable radical scavenger, tempol, reduces multiple organ injury in a rodent model of gram-positive shock. Crit Care Med 2000; 28: 1953-61.
43. Zacharowski K, Frank S, Otto M, et al. Lipoteichoic acid induces delayed protection in the rat heart: A comparison with endotoxin. Arterioscler Thromb Vasc Biol 2000; 20: 1521-8.
44. Kats S, Schonberger JP, Brands R, Seinen W, van Oeveren W. Endotoxin release in cardiac surgery with cardiopulmonary bypass: pathophysiology and possible therapeutic strategies. An update. Eur J Cardiothorac Surg 2011; 39: 451-8.
45. Eltzschig HK, Eckle T. Ischemia and Reperfusion-From Mechanism to Translation. Nat Med 2011: in press.
46. Warltier DC, al-Wathiqui MH, Kampine JP, Schmeling WT. Recovery of contractile function of stunned myocardium in chronically instrumented dogs is enhanced by halothane or isoflurane. Anesthesiology 1988; 69: 552-65.
47. Kersten JR, Brayer AP, Pagel PS, Tessmer JP, Warltier DC. Perfusion of ischemic myocardium during anesthesia with sevoflurane. Anesthesiology 1994; 81: 995-1004.
48. Liu R, Ishibe Y, Ueda M. Isoflurane-sevoflurane adminstration before ischemia attenuates ischemia-reperfusion-induced injury in isolated rat lungs. Anesthesiology 2000; 92: 833-40.
49. Landoni G, Fochi O, Bignami E, et al. Cardiac protection by volatile anesthetics in non-cardiac surgery? A meta-analysis of randomized controlled studies on clinically relevant endpoints. HSR Proc Intensive Care Cardiovasc Anesth 2009; 1: 34-43.
50. Eltzschig HK, Macmanus CF, Colgan SP. Neutrophils as sources of extracellular nucleotides: functional consequences at the vascular interface. Trends Cardiovasc Med 2008; 18: 103-7.
51. Weissmuller T, Campbell EL, Rosenberger P, et al. PMNs facilitate translocation of platelets across human and mouse epithelium and together alter fluid homeostasis via epithelial cellexpressed ecto-NTPDases. J Clin Invest 2008; 118: 3682-92.
52. Hasko G, Linden J, Cronstein B, Pacher P. Adenosine receptors: therapeutic aspects for inflammatory and immune diseases. Nat Rev Drug Discov 2008; 7: 759-70.
53. Colgan SP, Eltzschig HK, Eckle T, Thompson LF. Physiological roles for ecto-5'-nucleotidase (CD73). Purinergic Signal 2006; 2: 351-360.
54. Eckle T, Hughes K, Ehrentraut H, et al. Crosstalk between the equilibrative nucleoside transporter ENT2 and alveolar Adora2b adenosine receptors dampens acute lung injury. FASEB J 2013.
55. Eltzschig HK, Ibla JC, Furuta GT, et al. Coordinated adenine nucleotide phosphohydrolysis and nucleoside signaling in posthypoxic endothelium: role of ectonucleotidases and adenosine A2B receptors. J Exp Med 2003; 198: 783-96.
56. Eckle T, Faigle M, Grenz A, Laucher S, Thompson LF, Eltzschig HK. A2B adenosine receptor dampens hypoxia-induced vascular leak. Blood 2008; 111: 2024-35.
57. Lennon PF, Taylor CT, Stahl GL, Colgan SP. Neutrophil-derived 5'-adenosine monophosphate promotes endothelial barrier function via CD73-mediated conversion to adenosine and endothelial A2B receptor activation. J Exp Med 1998; 188: 1433-43.
58. Koeppen M, Eckle T, Eltzschig HK. Selective deletion of the A1 adenosine receptor abolishes heart-rate slowing effects of intravascular adenosine in vivo. PLoS One 2009; 4: e6784.
59. Eckle T, Grenz A, Kohler D, et al. Systematic evaluation of a novel model for cardiac ischemic preconditioning in mice. Am J Physiol Heart Circ Physiol 2006; 291: H2533-40.
60. Belhomme D, Peynet J, Louzy M, Launay JM, Kitakaze M, Menasche P. Evidence for preconditioning by isoflurane in coronary artery bypass graft surgery. Circulation 1999; 100: II340-4.
61. Roscoe AK, Christensen JD, Lynch C, 3rd. Isoflurane, but not halothane, induces protection of human myocardium via adenosine A1 receptors and adenosine triphosphate-sensitive potassium channels. Anesthesiology 2000; 92: 1692-701.
62. Cope DK, Impastato WK, Cohen MV, Downey JM. Volatile anesthetics protect the ischemic rabbit myocardium from infarction. Anesthesiology 1997; 86: 699-709.
63. Eckle T, Kohler D, Lehmann R, El Kasmi K, Eltzschig HK. Hypoxia-inducible factor-1 is central to cardioprotection: a new paradigm for ischemic preconditioning. Circulation 2008; 118: 166-75.
64. Braunwald E. On circadian variation of myocardial reperfusion injury. Circ Res 2012; 110: 6-7.
65. Reiter R, Swingen C, Moore L, Henry TD, Traverse JH. Circadian Dependence of Infarct Size and Left Ventricular Function After ST Elevation Myocardial Infarction. Circ Res 2012; 110: 105-10.
66. Suarez-Barrientos A, Lopez-Romero P, Vivas D, et al. Circadian variations of infarct size in acute myocardial infarction. Heart 2011.
67. Ibanez B, Suarez-Barrientos A, Lopez-Romero P. Circadian variations of infarct size in STEM1. Circ Res 2012; 110: e22; author reply e23.
68. Lopaschuk GD, Jaswal JS. Energy metabolic phenotype of the cardiomyocyte during development, differentiation, and postnatal maturation. J Cardiovasc Pharmacol 2010; 56: 130-40.
69. Staels B. When the Clock stops ticking, metabolic syndrome explodes. Nat Med 2006; 12: 54-5; discussion 55.